Outcomes for adolescent and young adult patients treated with pediatric-based vs adult-based treatment protocols
| Country . | Clinical trials, pediatric/adult . | Age range, y . | Survival: E or D . | Overall survival . | |
|---|---|---|---|---|---|
| Pediatric regimen . | Adult regimen . | Pediatric regimen/Adult regimen . | |||
| United States2 | CCG*/CALGB† | 16-21 | E: 63% at 7 y | E: 34% at 7 y | 67%/46% at 7 y |
| United States3 * | CCG100 series | 16-21 | E: 72% at 5 y | ||
| France4 | FRALLE93*/LALA94† | 15-20 | D: 68% at 6 y | D: 32% at 4 y | 78% at 6 y/45% at 4 y |
| France5 † | GRAALL 2003 | 15-60 | E: 55% at 4 y | 58% at 4 y/ | |
| Great Britain6 | ALL97*/UKALLXII† | 15-17 | E: 65% | E: 49% at 5 y | 71% at 5 y/56% at 5 y |
| United Kingdom7 † | MRC UKALLX, Xa/ | 15-20 | D: 35% at 5 y | 60% at 5 y/ | |
| The Netherlands8 | DCOG*/HOVON† | 15-18 | E: 69% at 5 y | E: 34% at 5 y | 79% at 5 y/38% at 5 y |
| Spain9 † | /ALL96 | 14-18 | /71% at 2 y | ||
| Italy10 * | AIEOP ALL95, 2000/ | 14-18 | 80% at 2 y/ | ||
| Country . | Clinical trials, pediatric/adult . | Age range, y . | Survival: E or D . | Overall survival . | |
|---|---|---|---|---|---|
| Pediatric regimen . | Adult regimen . | Pediatric regimen/Adult regimen . | |||
| United States2 | CCG*/CALGB† | 16-21 | E: 63% at 7 y | E: 34% at 7 y | 67%/46% at 7 y |
| United States3 * | CCG100 series | 16-21 | E: 72% at 5 y | ||
| France4 | FRALLE93*/LALA94† | 15-20 | D: 68% at 6 y | D: 32% at 4 y | 78% at 6 y/45% at 4 y |
| France5 † | GRAALL 2003 | 15-60 | E: 55% at 4 y | 58% at 4 y/ | |
| Great Britain6 | ALL97*/UKALLXII† | 15-17 | E: 65% | E: 49% at 5 y | 71% at 5 y/56% at 5 y |
| United Kingdom7 † | MRC UKALLX, Xa/ | 15-20 | D: 35% at 5 y | 60% at 5 y/ | |
| The Netherlands8 | DCOG*/HOVON† | 15-18 | E: 69% at 5 y | E: 34% at 5 y | 79% at 5 y/38% at 5 y |
| Spain9 † | /ALL96 | 14-18 | /71% at 2 y | ||
| Italy10 * | AIEOP ALL95, 2000/ | 14-18 | 80% at 2 y/ | ||